DISHMAN CARBOGEN AMCIS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.2 INR | +0.89% |
|
-5.77% | +29.54% |
| Apr. 01 | Dishman Carbogen Amcis Limited Announces Board Cessations | CI |
| Mar. 19 | Dishman Carbogen Amcis Arm Gets GMP Certificate from Brazilian Authority for Shanghai Site | MT |
| Sales 2022 | 21.41B 257M | Sales 2023 | 24.13B 290M | Capitalization | 19.56B 235M |
|---|---|---|---|---|---|
| Net income 2022 | 180M 2.16M | Net income 2023 | -298M -3.58M | EV / Sales 2022 | 2.02 x |
| Net Debt 2022 | 14.27B 171M | Net Debt 2023 | 19B 228M | EV / Sales 2023 | 1.6 x |
| P/E ratio 2022 |
161
x | P/E ratio 2023 |
-65.6
x | Employees | 1,295 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 29.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dishman Carbogen Amcis Limited
| 1 day | +0.89% | ||
| 1 week | -5.77% | ||
| Current month | -6.09% | ||
| 1 month | +2.12% | ||
| 3 months | +17.06% | ||
| 6 months | +43.20% | ||
| Current year | +29.54% |
1 week
213.45
234.00
1 month
213.45254.00
Current year
179.00282.95
1 year
113.25282.95
3 years
80.05282.95
5 years
46.45282.95
10 years
46.45396.55
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 38 | 12-04-06 | |
Harshil R. Dalal
DFI | Director of Finance/CFO | 42 | - |
Paolo Armanino
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 07-03-16 | |
| Director/Board Member | 73 | 17-03-16 | |
| Director/Board Member | 76 | 17-03-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 221.2 | +0.89% | 32,616 |
| 24-04-18 | 219.3 | -3.24% | 52,865 |
| 24-04-16 | 226.6 | -0.29% | 44,943 |
| 24-04-15 | 227.3 | -3.19% | 30,270 |
| 24-04-12 | 234.8 | -3.06% | 105,128 |
Delayed Quote Bombay S.E., April 19, 2024 at 06:00 am EDT
More quotes
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Companyâs segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q4 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- DCAL Stock
- 540701 Stock
